-
2
-
-
84860630975
-
Targeting the interleukin-6/Jak/stat pathway in human malignancies
-
Sansone P, Bromberg J: Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30:1005-1014, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 1005-1014
-
-
Sansone, P.1
Bromberg, J.2
-
3
-
-
84860238507
-
Dynamics and non-canonical aspects of JAK/STAT signalling
-
Mohr A, Chatain N, Domoszlai T, et al: Dynamics and non-canonical aspects of JAK/STAT signalling. Eur J Cell Biol 91:524-532, 2011
-
(2011)
Eur J Cell Biol
, vol.91
, pp. 524-532
-
-
Mohr, A.1
Chatain, N.2
Domoszlai, T.3
-
4
-
-
33847351136
-
The JAK-STAT signaling pathway: Input and output integration
-
Murray PJ: The JAK-STAT signaling pathway: Input and output integration. J Immunol 178:2623-2629, 2007
-
(2007)
J Immunol
, vol.178
, pp. 2623-2629
-
-
Murray, P.J.1
-
5
-
-
38949165127
-
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
-
Ding BB, Yu JJ, Yu RY, et al: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111:1515-1523, 2008
-
(2008)
Blood
, vol.111
, pp. 1515-1523
-
-
Ding, B.B.1
Yu, J.J.2
Yu, R.Y.3
-
6
-
-
20844433035
-
STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis
-
Holtick U, Vockerodt M, Pinkert D, et al: STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 19:936-944, 2005
-
(2005)
Leukemia
, vol.19
, pp. 936-944
-
-
Holtick, U.1
Vockerodt, M.2
Pinkert, D.3
-
7
-
-
78049370405
-
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
-
Green MR, Monti S, Rodig SJ, et al: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268-3277, 2010
-
(2010)
Blood
, vol.116
, pp. 3268-3277
-
-
Green, M.R.1
Monti, S.2
Rodig, S.J.3
-
8
-
-
43549097394
-
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma
-
Lam LT, Wright G, Davis RE, et al: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-3713, 2008
-
(2008)
Blood
, vol.111
, pp. 3701-3713
-
-
Lam, L.T.1
Wright, G.2
Davis, R.E.3
-
10
-
-
33846903838
-
Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease
-
O'Sullivan LA, Liongue C, Lewis RS, et al: Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 44:2497-2506, 2007
-
(2007)
Mol Immunol
, vol.44
, pp. 2497-2506
-
-
O'Sullivan, L.A.1
Liongue, C.2
Lewis, R.S.3
-
11
-
-
36148989576
-
Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6
-
Mottok A, Renné C, Willenbrock K, et al: Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 110:3387-3390, 2007
-
(2007)
Blood
, vol.110
, pp. 3387-3390
-
-
Mottok, A.1
Renné, C.2
Willenbrock, K.3
-
12
-
-
33646382121
-
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation
-
Weniger MA, Melzner I, Menz CK, et al: Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25:2679-2684, 2006
-
(2006)
Oncogene
, vol.25
, pp. 2679-2684
-
-
Weniger, M.A.1
Melzner, I.2
Menz, C.K.3
-
13
-
-
32144453842
-
JAK/STAT signal transduction: Regulators and implication in hematological malignancies
-
Valentino L, Pierre J: JAK/STAT signal transduction: Regulators and implication in hematological malignancies. Biochem Pharmacol 71:713-721, 2006
-
(2006)
Biochem Pharmacol
, vol.71
, pp. 713-721
-
-
Valentino, L.1
Pierre, J.2
-
14
-
-
15244350510
-
Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line
-
Melzner I, Bucur AJ, Brüderlein S, et al: Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105:2535-2542, 2005
-
(2005)
Blood
, vol.105
, pp. 2535-2542
-
-
Melzner, I.1
Bucur, A.J.2
Brüderlein, S.3
-
15
-
-
19944432663
-
Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors
-
Reddy J, Shivapurkar N, Takahashi T, et al: Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 24:732-736, 2005
-
(2005)
Oncogene
, vol.24
, pp. 732-736
-
-
Reddy, J.1
Shivapurkar, N.2
Takahashi, T.3
-
16
-
-
27144433826
-
Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma
-
Niwa Y, Kanda H, Shikauchi Y, et al: Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24:6406-6417, 2005
-
(2005)
Oncogene
, vol.24
, pp. 6406-6417
-
-
Niwa, Y.1
Kanda, H.2
Shikauchi, Y.3
-
17
-
-
0026465510
-
Activation of cytokines in Hodgkin's disease
-
Tesch H, Feller AC, Jucker M, et al: Activation of cytokines in Hodgkin's disease. Ann Oncol 4:13-16, 1992
-
(1992)
Ann Oncol
, vol.4
, pp. 13-16
-
-
Tesch, H.1
Feller, A.C.2
Jucker, M.3
-
18
-
-
0027421048
-
Cytokines in malignant lymphomas: Review and prospective evaluation
-
Hsu SM, Waldron JW Jr, Hsu PL, et al: Cytokines in malignant lymphomas: Review and prospective evaluation. Hum Pathol 24:1040-1057, 1993
-
(1993)
Hum Pathol
, vol.24
, pp. 1040-1057
-
-
Hsu, S.M.1
Waldron Jr., J.W.2
Hsu, P.L.3
-
19
-
-
79960178510
-
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5, 7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10, 12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma
-
William AD, Lee AC, Blanchard S, et al: Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6) .1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem 54:4638-4658, 2011
-
(2011)
J Med Chem
, vol.54
, pp. 4638-4658
-
-
William, A.D.1
Lee, A.C.2
Blanchard, S.3
-
20
-
-
80755140046
-
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
-
Hart S, Goh KC, Novotny-Diermayr V, et al: SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25:1751-1759, 2011
-
(2011)
Leukemia
, vol.25
, pp. 1751-1759
-
-
Hart, S.1
Goh, K.C.2
Novotny-Diermayr, V.3
-
21
-
-
33947496614
-
Revised response criteria for malignant lymphoma
-
Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
-
(2007)
J Clin Oncol
, vol.25
, pp. 579-586
-
-
Cheson, B.D.1
Pfistner, B.2
Juweid, M.E.3
-
22
-
-
80054028202
-
Long-term outcome of treatment with ruxolitinib in myelofibrosis
-
Tefferi A, Litzow MR, Pardanani A: Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365:1455-1457, 2011
-
(2011)
N Engl J Med
, vol.365
, pp. 1455-1457
-
-
Tefferi, A.1
Litzow, M.R.2
Pardanani, A.3
-
23
-
-
84861216420
-
Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post-myeloproliferative neoplasm acute myeloid leukemia
-
Eghtedar A, Verstovsek S, Estrov Z, et al: Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post-myeloproliferative neoplasm acute myeloid leukemia. Blood 119:4614-4618, 2012
-
(2012)
Blood
, vol.119
, pp. 4614-4618
-
-
Eghtedar, A.1
Verstovsek, S.2
Estrov, Z.3
-
24
-
-
84863393110
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
-
Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807, 2012
-
(2012)
N Engl J Med
, vol.366
, pp. 799-807
-
-
Verstovsek, S.1
Mesa, R.A.2
Gotlib, J.3
-
26
-
-
34249041983
-
Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: A study from the Groupe d'Etude des Lymphomes de l'Adulte
-
Casasnovas RO, Mounier N, Brice P, et al: Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: A study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:1732-1740, 2007
-
(2007)
J Clin Oncol
, vol.25
, pp. 1732-1740
-
-
Casasnovas, R.O.1
Mounier, N.2
Brice, P.3
-
27
-
-
77649297872
-
Proangiogenic cytokines produced by non-Hodgkin lymphoma tumor cells induce angiogenesis in infiltrated bone marrow samples
-
Etto LY, Silva MR, Dalboni MA, et al: Proangiogenic cytokines produced by non-Hodgkin lymphoma tumor cells induce angiogenesis in infiltrated bone marrow samples. Leuk Lymphoma 50:1381-1383, 2009
-
(2009)
Leuk Lymphoma
, vol.50
, pp. 1381-1383
-
-
Etto, L.Y.1
Silva, M.R.2
Dalboni, M.A.3
-
28
-
-
77955709652
-
Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: A prospective study
-
Gu Y, Shore RE, Arslan AA, et al: Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: A prospective study. Cancer Causes Control 21:1323-1333, 2010
-
(2010)
Cancer Causes Control
, vol.21
, pp. 1323-1333
-
-
Gu, Y.1
Shore, R.E.2
Arslan, A.A.3
-
29
-
-
79960394814
-
Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma
-
Purdue MP, Lan Q, Bagni R, et al: Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res 71:4898-4907, 2011
-
(2011)
Cancer Res
, vol.71
, pp. 4898-4907
-
-
Purdue, M.P.1
Lan, Q.2
Bagni, R.3
-
30
-
-
0028893151
-
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma
-
Stasi R, Zinzani L, Galieni P, et al: Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 54:9-17, 1995
-
(1995)
Eur J Haematol
, vol.54
, pp. 9-17
-
-
Stasi, R.1
Zinzani, L.2
Galieni, P.3
-
31
-
-
0028301226
-
Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors
-
DaSilva L, Howard OM, Rui H, et al: Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J Biol Chem 269:18267-18270, 1994
-
(1994)
J Biol Chem
, vol.269
, pp. 18267-18270
-
-
DaSilva, L.1
Howard, O.M.2
Rui, H.3
-
32
-
-
79951681794
-
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
-
Greystoke A, O'Connor JP, Linton K, et al: Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br J Cancer 104:719-725, 2011
-
(2011)
Br J Cancer
, vol.104
, pp. 719-725
-
-
Greystoke, A.1
O'Connor, J.P.2
Linton, K.3
|